C

CTI Biopharma Corp
F:CEPS

Watchlist Manager
CTI Biopharma Corp
F:CEPS
Watchlist
Price: 28 EUR Market Closed
Market Cap: 3.7B EUR

Net Margin

-106.1%
Current
Improving
by 35.7%
vs 3-y average of -141.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-106.1%
=
Net Income
$-69.2m
/
Revenue
$75.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-106.1%
=
Net Income
€-69.2m
/
Revenue
$75.8m

Peer Comparison

Country Company Market Cap Net
Margin
US
CTI Biopharma Corp
F:CEPS
3.7B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 12 771 companies
10th percentile
-106.1%
Low
-4 073 233.3% — -2.2%
Typical Range
-2.2% — 12.9%
High
12.9% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 073 233.3%
30th Percentile -2.2%
Median 5.2%
70th Percentile 12.9%
Max 1 135 400%

CTI Biopharma Corp
Glance View

Market Cap
3.7B EUR
Industry
Biotechnology

CTI BioPharma Corp. began its journey with a singular focus on transforming the landscape of treatment for blood-related cancers. Established with a commitment to innovation in the biotechnology sector, the Seattle-based company has strategically positioned itself as a pivotal player in developing novel therapies for hematologic malignancies. At the heart of its operations is its flagship product, Pixuvri (pixantrone), which gained initial traction in the European market as a treatment for certain types of aggressive non-Hodgkin lymphoma. This approval represented not only a milestone for the company but also a validation of its dedicated approach in addressing critical unmet needs within oncology. The company's revenue model pivots on the successful commercialization of its pharmaceutical innovations. Through strategic collaborations and licensing agreements, CTI BioPharma seeks to broaden the distribution reach and accessibility of its treatments. By leveraging partnerships within the pharmaceutical industry, CTI has aimed to augment its research capabilities and expand its market presence. This business approach underscores a sustainable pathway to profitability by aligning its innovations directly with the needs of healthcare providers and patients, thus ensuring that its scientific advances translate into tangible therapeutic options in the oncology space. By continually refining its product portfolio, the company maintains a dynamic stance in a rapidly evolving market, safeguarding its position and ensuring its growth trajectory.

CEPS Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-106.1%
=
Net Income
$-69.2m
/
Revenue
$75.8m
What is CTI Biopharma Corp's current Net Margin?

The current Net Margin for CTI Biopharma Corp is -106.1%, which is above its 3-year median of -141.8%.

How has Net Margin changed over time?

Over the last 3 years, CTI Biopharma Corp’s Net Margin has increased from -1 685.4% to -106.1%. During this period, it reached a low of -5 682.6% on Mar 31, 2022 and a high of -99.1% on May 1, 2023.

Back to Top